Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,591.90
(
0.54%
)
US TECH 100
23,504.00
(
0.62%
)
Dow Jones
46,429.49
(
0.66%
)
Brent Oil
98.78
(
2.36%
)
Bitcoin
71,099.99
(
0.83%
)
News Focus
News Focus
Post# of 257285
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122810
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 232992

Tuesday, 11/09/2021 1:18:52 PM

Tuesday, November 09, 2021 1:18:52 PM

Post# of 257285
Re: RVNC / VTRS Botox biosimilar

During yesterday’s VTRS 3Q21 CC, COO Rajiv Malik said VTRS and RVNC met with the FDA in Sep 2021 and obtained the FDA’s buy-in on the clinical data and analytics needed for an eventual 351(k) submission, which VTRS expects to occur in 2024. Malik further said that RVNC’s Daxi CRL will not affect the timing of the Botox-biosimilar program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today